Cerner (CERN) Banks On RCM & PH Platforms, Competition Rife
Zacks Investment Research | Sep 25, 2017 08:43AM ET
On Sep 22, we issued an updated research report on North Kansas City, MO-based Cerner Corporation (NASDAQ:CERN) – a leading global provider of healthcare information technology solutions (“HCIT”). The stock currently carries a Zacks Rank #3 (Hold).
We believe that Cerner has solid growth opportunities in the revenue cycle management (RCM) suite of solutions. In fact, the segment has been a strong contributor in recent times with RevWorks services delivering a solid performance. In fact, bookings in the second quarter of 2017 were $1.636 billion (an all-time high), up 16% on a year-over-year basis.
A secondary growth driver for Cerner is its Population Health (“PH”) Management platform. Notably, the company clinched a high number of large contracts for the PH platform in the last reported quarter.
Cerner offers exposure to worldwide healthcare automation. Its international operations provide a more diversified revenue stream. In the past, the company won contracts in the U.K. as well as the Middle East. Furthermore, Cerner constantly pursues complementary business acquisitions that enable it to expand solutions, device offerings and services.
On the flipside, the company operates in the HCIT space which is intensely competitive and fast evolving, subjecting it to rapid technological changes.
Share Price & Estimate Revision
Cerner had an impressive run on the bourse over the last six months, trading above the industry in terms of price performance. A glimpse at the price movement reveals that Cerner’s shares have gained 17.4%, comparing favorably with the 15.8% rise of the industry it belongs to.
On the flip side, the estimate revision trend for the current year remains unfavorable with eight estimates moving south over the last two months, compared with only two movement in the opposite direction. The company’s current estimate slipped 0.4% over the past two months.
Key Picks
A few better-ranked medical stocks are Edwards Lifesciences Corp. (NYSE:EW) , IDEXX Laboratories, Inc. (NASDAQ:IDXX) and Cogentix Medical, Inc. (NASDAQ:CGNT) .
While Edwards Lifesciences sports a Zacks Rank #1 (Strong Buy), IDEXX Laboratories and Cogentix Medical hold a Zacks Rank #2 (Buy). You can see Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.